Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Phase III trial of IMRT versus IMPT in oropharyngeal carcinoma

Shloma Koyfman • 3 Jun 2024
ASCO 2024
Head and Neck Cancer

Shloma Koyfman, MD, Cleveland Clinic, Cleveland, OH, shares the findings of a Phase III trial (NCT01893307) comparing intensity-modulated radiation therapy (IMRT) with intensity-modulated proton therapy (IMPT) in patients with oropharyngeal carcinoma (OPC). IMPT demonstrated non-inferiority to IMRT in terms of progression-free survival (PFS) and overall survival (OS). Additionally, IMPT reduced gastrostomy-tube dependence and malnutrition, establishing it as a standard of care for OPC. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Shloma Koyfman

Phase II PATHWay: adjuvant pembrolizumab in patients with HNSC cancer at high risk for recurrence
1:43
Phase II PATHWay: adjuvant pembrolizumab in patients with HNSC cancer at high risk for recurrence
Shloma Koyfman • 3 Jun 2024
Intra-treatment hypoxia directed major radiation de-escalation as definitive treatment for HPV+ OC
1:53
Intra-treatment hypoxia directed major radiation de-escalation as definitive treatment for HPV+ OC
Shloma Koyfman • 3 Jun 2024

Related Videos

Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC
1:04
Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC
Jacob Thomas • 31 May 2026
TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
2:24
TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
Ari Rosenberg • 31 May 2026
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
3:11
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
Nabil Saba • 1 Jun 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals